Showing 501 - 520 results of 120,669 for search '(( 2 e decrease ) OR ( 5 ((point decrease) OR (((nn decrease) OR (a decrease)))) ))', query time: 1.53s Refine Results
  1. 501

    Loss of Cntnap2 decreases specifically stabilization of new spines. by Amos Gdalyahu (3213810)

    Published 2015
    “…<p><b>a.</b> From left to right: Chronic imaging through a cranial window of L5 pyramidal neuron. …”
  2. 502

    The rate of lariat formation is decreased two-fold by isoginkgetin treatment. by Jesse M. Gray (527662)

    Published 2014
    “…The height of each bar indicates the fold change, from vehicle- to isoginkgetin-treated cells, in the mean fraction of reads aligning to each genic feature (<i>p</i><0.02 from two-tailed <i>t</i>-tests for all ratios). (<b>B</b>) Isoginkgetin treatment increases the “guillotine” base height (<i>p</i> = 10<sup>−12</sup>) of intronic expression without increasing the blade height (<i>p</i> = 0.5), consistent with a splicing defect (compare to <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0089673#pone-0089673-g001" target="_blank">Fig. 1A</a>). …”
  3. 503
  4. 504
  5. 505
  6. 506

    Vasopressin decreases EPSPs in CA2 after LTP induction. by Magda Chafai (295116)

    Published 2013
    “…</i> time showing that AVP did not affect the basal EC LIII-CA2 EPSP recorded before HFS stimulation. E) Left, Typical graph of the fEPSP evoked by Schaffer collaterals stimulation and recorded in a CA1 pyramidal neuron (SC-CA1); AVP did not affect the amplitude of the LTP-potentiated EPSP , as shown on the average graph (Right, n = 4).…”
  7. 507
  8. 508
  9. 509

    (A) The proportion of fast MyHC myotubes is decreased in Igf-2 deficient mice (maternal disomy Chromosome 7 - MatDi) at E14 by Deborah Merrick (54928)

    Published 2011
    “…(B) Embryo immunoblotting for Igf-2 demonstrates a stage related increase in Igf-2 protein between E10.5 and E15.5 in WT and absence of Igf-2 in MatDi embryos at E14.5 and E15.5 Tracks 1–4 E10.5, E13.5, E14.5 and E15.5 WT embryos respectively, Track 5 E14.5 MatDi, Track 6 E15.5 MatDi and Track 7 E15.5 WT. …”
  10. 510

    VRK1 overexpression is seen in human breast cancer and is associated with decreased relapse-free survival. by Aye M. Mon (5714912)

    Published 2018
    “…<b>(D)</b> HR [hazard ratio] of 1.72, p<1x10<sup>-16</sup>). <b>(E)</b> Similar analysis of 2,061 patients with ER<sup>+</sup> breast cancer (HR 1.48, p = 5.5x10<sup>-6</sup>). …”
  11. 511
  12. 512
  13. 513
  14. 514
  15. 515
  16. 516
  17. 517

    Ibuprofen and diclofenac decrease proliferation. by Verena Leidgens (815986)

    Published 2015
    “…<p>Proliferation was analyzed using crystal violet staining and results were verified via the CyQuant Direct Cell Proliferation assay in HTZ-349. (A) Starting at 72 h, all ibuprofen concentrations (0.5, 1, 2 mM) resulted in significant reduction of HTZ-349 proliferation (compared to non-treated Ctrl, 95% CI, p < 0.05). 2 mM ibuprofen caused significant proliferation inhibition at 24 h (0.01 > p ≤ 0.001) and 48 h (p < 0.0001). …”
  18. 518
  19. 519

    WT1 siRNA decreases proliferation, pAKT, and Bcl2 expression. by Ayana E. Morales (17756335)

    Published 2024
    “…</b> RT-qPCR of WT1, p<0.05(*), vFLIP(ns), LANA, p<0.0001(****), K8.1, p<0.0001(****), and BCL2 p<0.05(*) in the setting of WT1 knockdown in ISLK BAC-16 with WT1 siRNA in comparison to a control siRNA using two-sided, unpaired student’s t-tests. …”
  20. 520